Literature DB >> 3362369

Steroid-induced CT changes in patients with recurrent malignant glioma.

J G Cairncross1, D R Macdonald, J H Pexman, F J Ives.   

Abstract

The magnitude and time course of steroid-induced CT changes were analyzed in 11 patients with recurrent malignant glioma. CTs were obtained before and at regular intervals after starting dexamethasone (16 mg/d). Midline shift, ventricular compression, edema, enhancement intensity, and the size of the enhancing mass often improved with steroid treatment. Improvement occurred within 2 weeks in most instances. Changes in the volume of the enhancing tumor were assessed quantitatively in eight patients. In six, the mass was smaller after 2 weeks of steroid therapy, and in two the reduction approached 50%. Steroid-induced CT changes can mimic treatment responses. If steroids are necessary for symptom control, patients should be taking these medications for 2 weeks before a baseline CT is obtained and investigational treatment started.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3362369     DOI: 10.1212/wnl.38.5.724

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.

Authors:  K Anders; G G Grabenbauer; U Schuchardt; R Fahlbusch; R Fietkau; R Sauer; P Krauseneck
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.

Authors:  Susan M Chang; Sharon L Reynolds; Nicholas Butowski; Kathleen R Lamborn; Jan C Buckner; Richard S Kaplan; Darell D Bigner
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

3.  MRI and thallium-201 SPECT in the prediction of survival in glioma.

Authors:  Maaike J Vos; Johannes Berkhof; Otto S Hoekstra; Ingeborg Bosma; Eefje M Sizoo; Jan J Heimans; Jaap C Reijneveld; Esther Sanchez; Frank J Lagerwaard; Jan Buter; David P Noske; Tjeerd J Postma
Journal:  Neuroradiology       Date:  2011-07-14       Impact factor: 2.804

Review 4.  Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome.

Authors:  M S Berger; R C Rostomily
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

5.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Authors:  Patrick Y Wen; Timothy F Cloughesy; Benjamin M Ellingson; David A Reardon; Howard A Fine; Lauren Abrey; Karla Ballman; Martin Bendszuz; Jan Buckner; Susan M Chang; Michael D Prados; Whitney B Pope; Alma Gregory Sorensen; Martin van den Bent; Wai-Kwan Alfred Yung
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

6.  Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.

Authors:  R-E Yoo; S H Choi; T M Kim; S-H Lee; C-K Park; S-H Park; I H Kim; T J Yun; J-H Kim; C H Sohn
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-20       Impact factor: 3.825

Review 7.  Response assessment challenges in clinical trials of gliomas.

Authors:  Patrick Y Wen; Andrew D Norden; Jan Drappatz; Eudocia Quant
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

Review 8.  Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Authors:  John H Rossmeisl; Paulo A Garcia; Gregory B Daniel; John Daniel Bourland; Waldemar Debinski; Nikolaos Dervisis; Shawna Klahn
Journal:  Vet Radiol Ultrasound       Date:  2013-11-13       Impact factor: 1.363

9.  Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.

Authors:  Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

10.  End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

Authors:  Martin J van den Bent; Michael A Vogelbaum; Patrick Y Wen; David R Macdonald; Susan M Chang
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.